NetScientific appoints Charles Spicer to its Board as Independent Director and Chair-designate

– UK, London –  NetScientific plc (LON: NSCI), the investment and commercialization group, today announced the addition of Charles Spicer to its Board as an Independent Non-Executive Director and Chair-designate with immediate effect, to replace Interim Non-Executive Chair, Jonathan Robinson at 2023 AGM around 29 June 2023.

Charles Spicer will also chair the Nominations Committee and join the Audit Committee and the Remuneration Committee as a member.

Jonathan Robinson will remain on the Board as the Senior Independent Director and Chair of the Audit Committee and the Remuneration Committee.

About Charles Alexander Evan Spicer

Charles Spicer is an experienced chair and director specializing in the MedTech and life sciences industries. He advises both public and private companies. He currently chairs Creo Medical Group plc, IXICO plc, and Korn Wall Limited. Furthermore, he serves as the Chair of the UK Department of Health’s Product Development Awards Selection Panel B for Invention for Innovation (i4i). Charles previously held directorships at Aircraft Medical (acquired by Medtronic Inc. in 2015) and Stanmore Implants (acquired by Stryker Inc. in 2016).

Charles was previously Chief Executive of MDY Healthcare plc, a strategic healthcare investor, and Head of Healthcare Corporate Finance at both Numis Securities and Nomura International. Charles has a Ph.D. in History from London University and an MA in History from Cambridge University.

About NetScientific

NetScientific plc is an investment and commercialization group with an international portfolio of innovative life science, sustainability, and technology companies.

NetScientific identifies, invests in, and builds high-growth companies in the UK and internationally. The company adds value by proactively managing its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet, and syndicating investments through its wholly-owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.